Chiricozzi A, Gori N, Di Nardo L, et al. - In atopic dermatitis (AD) cases, certain treatment response parameters to dupilumab therapy could be negatively impacted by AD localization in exposed areas at the baseline as well as by AD persistency at the head/neck.

• Adult patients (n=41) with moderate to severe AD were included to assess the clinical response to dupilumab based on the presence or persistency of AD skin manifestations in specific body areas.

• Although disease amelioration was evident, there was a significantly lower probability of achieving an Eczema Area Severity Index (EASI) ≤1 in relation to baseline head/neck and hand localization.

• A significantly lower response was seen in cases with head/neck persistency vs those without, in terms of both mean EASI and Dermatology Life Quality Index reduction.